POSTER: MPN-794 Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor-Naive Patients With Myelofibrosis: 72-Week Follow-Up With Long-Term Efficacy Outcomes of the Phase 3 Manifest-2 Study
Year: 2025
Type: article
Authors: Raajit K. Rampal, AlessandroM. Vannucchi, Dominik Chraniuk, Sebastian Grosicki, Elisabetta Abruzzese, Sung-Eun Lee, Alessandro Lucchesi, Aaron Gerds, Stephen T. Oh, Andrea Patriarca, Alberto Álvarez Larrán, David Lavie, Vikas Gupta, Andrew T. Kuykendall, Prithviraj Bose, Moshe Talpaz, Francesca Palandri, Ruben Mesa, Jean-Jacques Kiladjian, Monika Wroclawska, Qing Li, Harald Maier, Claire Harrison, John Mascarenhas
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413780272